Last reviewed · How we verify
NCT04221893
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA trial testing Radiation Therapy (RT) in Stage IV Esophageal Adenocarcinoma in 28 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 7 August 2020 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 April 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Radiation Therapy (RT)
Conditions studied
- Stage IV Esophageal Adenocarcinoma — all drugs for Stage IV Esophageal Adenocarcinoma →
- Stage IV Esophageal Squamous Cell Carcinoma — all drugs for Stage IV Esophageal Squamous Cell Carcinoma →
- Stage IV Gastric Cancer — all drugs for Stage IV Gastric Cancer →
- Stage IV Adenocarcinoma of the Gastroesophageal Junction — all drugs for Stage IV Adenocarcinoma of the Gastroesophageal Junction →
Sponsor
University of California, San Francisco
Who can join
18 and older, any sex, with Stage IV Esophageal Adenocarcinoma or Stage IV Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?
Link B, Torres Crigna A, Hölzel M, Giordano FA, et al · · 2021 · cited 20× · PMID 34768644 · DOI 10.3390/jcm10215124 -
A narrative review of combining radiation and immunotherapy in gastroesophageal cancers.
Yoon K, Chen YJ, Chao J. · · 2021 · cited 3× · PMID 35116572 · DOI 10.21037/tcr-20-2210
Verify or expand the search:
- PubMed search for NCT04221893
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiation Therapy (RT)
Trials testing the same drug.
- NCT06504381 — DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma · Phase 1, PHASE2 · recruiting
- NCT05464667 — Preoperative Irradiation for Stage I Breast Cancer · NA · recruiting
- NCT03367715 — Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma · Phase 2 · completed
- NCT03437161 — A Prospective Trial to Compare Deep Inspiratory Breath Hold (DIBH) With Prone Breast Irradiation · NA · completed
- NCT02768558 — Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC · Phase 3 · terminated
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04221893 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04221893.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing